May 8, 2018

About Us

LYNDRA THERAPEUTICS

REINVENTING MEDICINES FOR A HEALTHIER WORLD

team

Dr Patricia Hurter

CEO | Member of the Board

Jessica Ballinger

President | Chief Operations Officer

Raymond
Knox

Chief Manufacturing Officer

Dr Richard Scranton

Chief Medical
Officer

Dr Örn Almarsson

Chief Technology
Officer

Abigail
Jenkins

Chief Commercial & Business Officer

Susan
Birdsey

SVP, People &
Culture

Jennifer
McGovern

SVP, Alliance & Program Management

Dr Mary Christian

SVP, Regulatory, Quality & Compliance

Dana
Vittum

VP,
Finance

Dr Tyler
Grant

Sr Director,
Engineering | Founding Employee

Dr Rosemary Kanasty

Director, Platform Discovery | Founding Employee

Board of Directors

Catherine B. Reynolds

Chair of the Board

Dr Robert Langer

Co-Founder | Member of the Board

Amy
Schulman

Executive Chair of the Board | Co-Founder

Dr Giovanni Traverso

Co-Founder| Member of the Board

Dr Patricia Hurter

CEO | Member of the Board

Douglas Dachille

Member of the Board

Dr Zafrira Avnur

Member of the Board

Jillian Moo-Young

Member of the Board

Company advisors

Dr Andrew Bellinger

Co-Founder | Advisor

Dr Bernard Silverman

Advisor

Dr Joga Gobburu

Advisor

Dr Edmund Harrigan

Advisor

Dr Thomas Laughren

Advisor

Dr Peter Belafsky

Advisor

Dr Ian Wilding

Advisor

Company Timeline

Founded on technology developed within the MIT lab  of Dr. Robert Langer in collaboration with the Bill & Melinda Gates Foundation
Platform and single agent preclinical in 2 species
($0.3 M NIH Grant)
Demonstrated gastric residence achievable with desired pharmacokinetics-single agent
($23 M Series A, $105 M AbbVie Partnership, $6 M NIH Grant(s), $4 M BMGF Grant) 
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – single agent
($18 M NIH Grant(s), $13 M BMGF Grant)
Demonstrated once-weekly dosage form can safely reside in the stomach with predictable pharmacokinetics – two agents in one capsule and preliminary food effects
($60 M Series B, $122 M Gilead Partnership, $19M NIH Grant, $3 M DoD Grant)
Expanded pipeline, repeat dosing, and food effects
($2M BMGF Grant, $1M NIH Grant)
Initiating pivotal studies, expanding clinical pipeline, and scaling up commercial manufacturing

 

 

 

 

investors & partners